J. Woodworth

发表

[Lys(B28), Pro(B29)]‐human insulin: Effect of injection time on postprandial glycemia

D. Howey, R. Bowsher, Rocco L. Brunelle, 1995, Clinical pharmacology and therapy.

Graphical human insulin time-activity profiles using standardized definitions.

J H Anderson, J. Anderson, J. Woodworth, 2001, Diabetes technology & therapeutics.

Relating glucose clamp profiles to reduction of blood glucose after insulin administration.

D. Howey, R. Bowsher, R. Brunelle, 2004, Diabetes technology & therapeutics.

Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer

D. Ouellet, A. Periclou, R. Johnson, 2000, Cancer Chemotherapy and Pharmacology.

Clinical Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mixtures

P. Roach, J. Woodworth, 2002, Clinical pharmacokinetics.

The Action Profile of Lispro Is Not Blunted by Mixing in the Syringe With NPH Insulin

S. Amiel, M. Evans, J. Woodworth, 1998, Diabetes Care.

Establishment of Time-Action Profiles for Regular and NPH Insulin Using Pharmacodynamic Modeling

D. Howey, R. Bowsher, J. Woodworth, 1994, Diabetes Care.

The Polymorphic Metabolism of Dextromethorphan

L. Moore, J. Woodworth, S. Dennis, 1987, Journal of clinical pharmacology.

Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.

L Heinemann, T Heise, L. Heinemann, 1999, Diabetes care.

Relative bioavailability of immediate- and sustained-release hydralazine formulations.

T. Ludden, A. Shepherd, J. Woodworth, 1988, Journal of pharmaceutical sciences.

A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.

G. Schwartz, L. Saltz, E. Casper, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

Suzanne F. Jones, D. V. Von Hoff, H. Burris, 1999, Cancer Chemotherapy and Pharmacology.

A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.

P. Vasey, S. Kaye, A. Calvert, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bioavailability Evaluation of a Controlled‐Release Dextromethorphan Liquid

J. Woodworth, L. Amsel, S. Dennis, 1987, Journal of clinical pharmacology.

Improved glucose control following administration of a 75% insulin lispro/25% NPL mixture in patients with type 1 diabetes

P. Roach, J. Woodworth, U. Gudat, 2000 .

Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin

J. Thijssen, D. Erkelens, B. Cerimele, 1996, Diabetes Care.

14C-Isomazole Disposition in Man After Oral Administration

J. Woodworth, S. Oldham, A. Delong, 1991, Pharmaceutical Research.

BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience

M. Beeram, M. Saif, D. V. Hoff, 2008 .

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

H. Black, J. Woodworth, J. Wolny, 1992, Antimicrobial Agents and Chemotherapy.

Radioimmunoassay for phencyclidine (PCP) in serum.

M. Mayersohn, J. Woodworth, S. Owens, 1982, Clinical chemistry.

Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challenge.

T. Ludden, A. Shepherd, J. Woodworth, 1992, Journal of pharmaceutical sciences.

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

H. Burris, F. A. Dorr, F A Dorr, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of ethanol and Δ9‐tetrahydrocannabinol on phencyclidine disposition in dogs

J. Woodworth, P. Godley, E. Moore, 1991 .

Sensitive RIA for the specific determination of insulin lispro.

R. Chance, R. Bowsher, P. Santa, 1999, Clinical chemistry.

Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin

L. Heinemann, T. Heise, C. Weyer, 1998, Diabetes Care.

Phencyclidine blood protein binding: influence of protein, pH and species.

M. Mayersohn, J. Woodworth, S. Owens, 1983, The Journal of pharmacology and experimental therapeutics.

Phencyclidine (PCP) disposition kinetics in dogs as a function of dose and route of administration.

M. Mayersohn, J. Woodworth, S. Owens, 1985, Journal of Pharmacology and Experimental Therapeutics.

Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers.

M. Seger, J. Holcombe, R. Bowsher, 1999, Journal of pharmaceutical sciences.

Quantitative analysis of phencyclidine and metabolites by capillary column gas chromatography.

M. Mayersohn, J. Woodworth, S. Owens, 1984, Journal of analytical toxicology.

A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes

P. Roach, B. Cerimele, J. Woodworth, 2003, Diabetic medicine : a journal of the British Diabetic Association.